218 related articles for article (PubMed ID: 15145177)
1. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
[TBL] [Abstract][Full Text] [Related]
2. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
Fujita T; Teh BS; Timme TL; Mai WY; Satoh T; Kusaka N; Naruishi K; Fattah EA; Aguilar-Cordova E; Butler EB; Thompson TC
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):84-90. PubMed ID: 16472937
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
4. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.
Miles BJ; Shalev M; Aguilar-Cordova E; Timme TL; Lee HM; Yang G; Adler HL; Kernen K; Pramudji CK; Satoh T; Gdor Y; Ren C; Ayala G; Wheeler TM; Butler EB; Kadmon D; Thompson TC
Hum Gene Ther; 2001 Nov; 12(16):1955-67. PubMed ID: 11686937
[TBL] [Abstract][Full Text] [Related]
6. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
[TBL] [Abstract][Full Text] [Related]
7. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
9. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer.
Nasu Y; Bangma CH; Hull GW; Yang G; Wang J; Shimura S; McCurdy MA; Ebara S; Lee HM; Timme TL; Thompson TC
Prostate Cancer Prostatic Dis; 2001; 4(1):44-55. PubMed ID: 12497062
[TBL] [Abstract][Full Text] [Related]
10. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
11. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
12. Cytopathic effect of in situ gene therapy in prostate cancer.
Ayala G; Wheeler TM; Shalev M; Thompson TC; Miles B; Aguilar-Cordova E; Chakraborty S; Kadmon D
Hum Pathol; 2000 Jul; 31(7):866-70. PubMed ID: 10923926
[TBL] [Abstract][Full Text] [Related]
13. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
14. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment.
Hasenburg A; Tong XW; Rojas-Martinez A; Nyberg-Hoffman C; Kieback CC; Kaplan AL; Kaufman RH; Ramzy I; Aguilar-Cordova E; Kieback DG
Anticancer Res; 1999; 19(3B):2163-5. PubMed ID: 10472325
[TBL] [Abstract][Full Text] [Related]
15. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
[TBL] [Abstract][Full Text] [Related]
16. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer.
Chhikara M; Huang H; Vlachaki MT; Zhu X; Teh B; Chiu KJ; Woo S; Berner B; Smith EO; Oberg KC; Aguilar LK; Thompson TC; Butler EB; Aguilar-Cordova E
Mol Ther; 2001 Apr; 3(4):536-42. PubMed ID: 11319915
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
19. Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity.
Lee YJ; Lee H; Borrelli MJ
Cancer Gene Ther; 2002 Mar; 9(3):267-74. PubMed ID: 11896443
[TBL] [Abstract][Full Text] [Related]
20. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
